Pharma’s repatriation dilemma: Simply pouring more money into the same business model that has not substantially improved outcomes in 40 years is unlikely to do so now.
Pharma’s repatriation dilemma: Simply pouring more money into the same business model that has not substantially improved outcomes in 40 years is unlikely to do so now.